Table 2 Details of the 15 discrepant tumours (13 patients) for HER2 status

From: Discrepancies in central review re-testing of patients with ER-positive and HER2-negative breast cancer in the OPTIMA prelim randomised clinical trial

 

Central HER2 results

Patient

HER2 status

Her2 : CEP17 ratio

Average CEP17 copy number per cell

Average Her2 copy number per cell

Comments

D

Amplified

3.59

1.10

3.95

Also ER-negative on central testing

H

Borderline amplified

2.00

2.78

5.55

 

I1a

Borderline amplified

2.14

1.65

3.53

 

I2a

Borderline amplified

2.06

1.69

3.47

 

J

Borderline amplified

2.20

1.43

3.14

 

K

Amplified

2.70

2.00

5.40

 

L

Amplified

2.39

1.55

3.70

 

M

Amplified

2.81

1.35

3.80

Heterogeneous – testing of core (locally) and second block (centrally) showed Her2 non-amplified foci.

N

Amplified

3.23

2.80

9.05

 

O1a

Amplified

2.78

1.35

3.75

 

O2a

Borderline amplified

2.11

1.40

2.95

 

P

Amplified

2.45

1.10

2.70

 

Q

Amplified

2.64

1.08

2.83

 

R

Amplified

3.92

1.85

7.25

 

S

Borderline amplified

2.11

2.03

4.30

 
  1. Abbreviations: CEP17=chromosome 17 centromeric probe; ER=oestrogen receptor; HER2=human epidermal growth factor receptor homologue 2.
  2. Amplified: HER2 to CEP17 ratio >2.20; borderline amplified: HER2 to CEP17 ratio 2.00–2.20.
  3. aG1 and G2, and N1 and N2, are tumours from the same patients, respectively.
Back to article page